Lipids, inflammation, and chronic kidney disease: a SHARP perspective
Accumulating evidence indicates that inflammation plays a role in the initiation and progression of chronic kidney disease. In the Study of Heart and Renal Protection (SHARP) trial, higher baseline C-reactive protein and higher baseline low-density lipoprotein cholesterol levels were both associated with a higher risk of cardiovascular events, but higher baseline C-reactive protein levels were also associated with a higher risk of nonvascular events. Simvastatin/ezetimibe reduced cardiovascular events independent of baseline C-reactive protein levels.
Source: Kidney International - Category: Urology & Nephrology Authors: David D. Waters, Liffert Vogt Tags: Commentary Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Chronic Kidney Disease | Heart | Simvastatin | Statin Therapy | Study | Urology & Nephrology | Vytorin | Zetia | Zocor